Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM

Diabetes

Volumn 45, Issue 11, 1996, Pages 1631-1634

  Greenbaum, Carla J ^a,b   Kahn, Steven E ^a   Palmer, Jerry P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDURAMIDE; NICOTINAMIDE; PANCREAS ISLET CELL ANTIBODY; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; PHARMACEUTICS; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 0029919434     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.11.1631     Document Type: Article

References (32)

1. Greenbaum CJ, Brooks-Worrell BM, Palmer JP, Leramark A: Autoimmunity and prediction of insulin dependent diabetes mellitus. In Diabetes Annual/8. Marshall SM, Home PD, Eds. Amsterdam, Elsevier, 1994, p. 21-54
2. DPT-1-Study-Group: The diabetes prevention trial of type I diabetes (DPT-1) (Abstract). Diabetes 43 (Suppl. 1):159A, 1994
3. DPT-1-Study-Group: The diabetes prevention trial of type I diabetes (DPT-1): implementation of screening and staging of relatives (Abstract). Diabetes 44 (Suppl. 1):129A, 1995
4. Haastert B, Giani G: On the sequential design of the Deutsche Nikotinamid Interventionsstudie: DENIS. Diabete Metab 19:100-104, 1993
5. L'evy-Marchal C: Cost benefit of screening for type 1 diabetes: a futuristic scenario. Diabete Metab 19:538-545, 1993
6. Chen M, Bergman RN, Pacini G, Porte D Jr: Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta cell function. J Clin Endocrinol Metab 60:13-20, 1985
7. Olefsky JM, Kolterman OG, Scarlett JA: Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am J Physiol 243:E15-E30, 1982
8. Beard JC, Ward WK, Halter JB, Wallum BJ, Porte D Jr: Relationship of islet function to insulin action in human obesity. J Clin Endocrinol Metab 65:59-64, 1987
9. McCulloch DK, Kahn SE, Schwartz MW, Koerker DJ, Palmer JP: Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J Clin Invest 87:1395-1401, 1991
10. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ Jr, Porte D Jr: Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562-568, 1989
11. Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte DJ: Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab 74:192-197, 1992
12. Korsgren O, Andersson A, Sandler S: Pretreatment of fetal porcine pancreas in culture with nicotinamide accelerates reversal of diabetes after transplantation to nude mice. Surgery 113:205-214, 1993
13. Burkart V, Koike T, Brenner HH, Kolb H: Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 35:1028-1034, 1992
14. Okamoto H: The role of poly (ADP-ribose) synthetase in the development of insulin-dependent diabetes and islet B-cell regeneration. Biomed Biochim Acta 44:15-20, 1985
15. Yonemura Y, Takashima T, Miwa K, Miyazaki I, Yamamoto H, Okamoto H: Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors: evidence of islet β-cell regeneration. Diabetes 33:401-404, 1984
16. Yamada K, Inada C, Otabe S, Takane N, Hayashi H, Nonaka K: Effects of free radical scavengers on cytokine actions on islet cells. Acta Endocrinol 128:379-384, 1993
17. Otsuka A, Hanafusa T, Miyagawa J, Kono N, Tarui S: Nicotinamide and 3-aminobenzamide reduce interferon-gamma-induced class II MHC (HLA-DR and -DP) molecule expression on cultured human endothelial cells and fibroblasts. Immunopharmacol Immunotoxicol 13:263-280, 1991
18. Hiromatsu Y, Sato Y, Tanaka K, Ishisaka N, Kamachi J, Nonaka K: Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells. Immunology 80:330-332, 1993
19. Andersen HU, Jorgensen KH, Egeberg J, Mandrup-Poulsen T, Nerup J: Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 43:770-777, 1994
20. Paul TL, Hramiak IM, Mahon JL, Freeman D, Atkinson P, Finegood DT, Dupre J: Nicotinamide and insulin sensitivity (Letter). Diabetologia 36:369, 1993
21. Bingley PJ, Caldas G, Bonfanti R, Gale EA: Nicotinamide and insulin secretion in normal subjects. Diabetologia 36:675-677, 1993
22. McCulloch DK, Klaff LJ, Kahn SE, Schoenfeld SL, Greenbaum CJ, Mauseth RS, Benson EA, Nepom GT, Shewey L, Palmer JP: Nonprogression of subclinical β-cell dysfunction among first-degree relatives of IDDM patients: 5-yr follow-up of the Seattle Family Study. Diabetes 39:549-556, 1990
23. Beard JC, Bergman RN, Ward WK, Porte D Jr: The insulin sensitivity index in nondiabetic man: correlation between clamp-derived and IVGTT-derived values. Diabetes 35:362-369, 1986
24. Morgan CR, Lazarow A: Immunoassay of insulin: two antibody system: plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes 12:115-136, 1963
25. Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 236:E667-E677, 1979
26. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
27. Ludvik B, Nolan J, Baloga J, Sacks D, Olefsky J: Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 44:1121-1125, 1995
28. Cutfield W, Bergman R, Menon R, Sperling M: The modified minimal model: application to measurement of insulin sensitivity in children. J Clin Endocrinol Metab 70:1644-1650, 1990
29. Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, Chaussain JL, Bach JF: Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39:1264-1272, 1990
30. Assan R, Feutren G, Sirmai J, Laborie C, Boitard C, Vexiau P, Du-Rostu H, Rodier M, Figoni M, Vague P, Hors J, Bach J-F: Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 39:768-774, 1990
31. Burcelin RG, Eddouks M, Beylot M, Normand S, Boitard C, Feutren G, Landais P, Riou JP, Girard JR, Bach JF, Assan RI: Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients. Diabetes Care 16:881-888, 1993
32. Pozzilli P, Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Fioriti E, Signore A, Cavallo MG, Andreani D, Lucentini L: Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1): The IMDIAB Study Group. Diabetic Med 11:98-104, 1994